← Back to Treatments
🏅 FDA Orphan Designation

TAKHZYRO

LANADELUMAB-FLYO

Manufacturer: Takeda Pharmaceuticals America, Inc.

Indicated for:
Hereditary angioedema

FDA-Approved Indications (1)

indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older

Population: adult and pediatric patients aged 2 years and older

Indications & Usage

1 INDICATIONS AND USAGE TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. ( 1 )

💙 Support Programs

View all →
TAKHZYRO
Takeda
Apply ↗
TAKHZYRO
Takeda Pharmaceuticals America, Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.